Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1995-2-9
|
| pubmed:abstractText |
The current status of interferon (IFN) therapy in chronic hepatitis C is presented, focusing on the results of studies in Japan. Depending on the IFN treatment regimen used in chronic hepatitis C, it is possible to eradicate HCV in a relatively high percentage of patients (about 40%) and to achieve a cure for chronic hepatitis C. The objective of treatment should therefore be the eradication of HCV. The efficacy of IFN in chronic hepatitis C is dependent on the dosage of IFN, duration of treatment, liver histology findings, serum HCV-RNA levels, and HCV genotype. Besides a flu-like syndrome, many adverse reactions are associated with high-dose, long-term IFN treatment. However, as a rule, full recovery or improvement follows prompt withdrawal of IFN. By modification of the IFN, it will be possible to reduce adverse reactions and to create a more effective IFN to further enhance the effect of IFN in chronic hepatitis C.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0300-5526
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
37
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
87-100
|
| pubmed:dateRevised |
2005-11-16
|
| pubmed:meshHeading | |
| pubmed:year |
1994
|
| pubmed:articleTitle |
Current state of interferon therapy for chronic hepatitis C.
|
| pubmed:affiliation |
Institute of Medical Science, St. Marianna, University School of Medicine, Kawasaki, Japan.
|
| pubmed:publicationType |
Journal Article,
Review
|